ProMetic Life Sciences Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ProMetic Life Sciences

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Leo Fisher who wrote (154)	12/3/2017 6:54:14 AM
From: axial	of 250

Thanks, Leo — "Dilutions do hurt a bit". Agreed. As many have noted, a Rights Offering would have been preferable to the Structured Alpha deal. With its huge existing investment in Prometic -- and consequent influence on Prometic decisions -- perhaps Structured Alpha itself objected to this alternative. In any case it's done. For the near-term, financial risk has moderated. Meanwhile the pipeline improves month-by-month. In parallel, the short campaign continues unabated, despite occasional whoops of victory on other threads. There doesn't seem to be widespread understanding that such campaigns can last for years -- and pointing it out is useless. It won't stop soon, and may even continue after Ryplazim is approved, until the product demonstrates traction and steady increasing revenues. When the short campaign finally ends and the price begins to climb, dilution will show its face. We can expect major shareholders such as Structured Alpha to sell into price gains, acting as a brake on share appreciation. Nevertheless, long-term the attraction of a great pipeline rules. By 2020, the picture should be a lot better. But it ain't gonna be fast or easy. Jim

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next